Featured Archives - Inceptua Group

Safely and Reliably Supplying your Comparator Needs during COVID19

Maintaining Safe and Reliable Supply of Comparators during COVID19 As an agile, well-distributed and robust global supplier of Comparators for the biopharmaceutical industry, Inceptua is uniquely positioned to safely and…

Inceptua GroupOctober 28, 2020

Featured Inceptua Pharma Update

Helping get orphan drugs to patients quicker

Across Europe there is disparity in the average time for new drugs to be approved and accessible to patients. There are a number of factors delaying these processes. Stuart Bell,…

Stuart BellOctober 7, 2020

Featured Press release

Inceptua receives approval of marketing authorization transfer of Jetrea® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion

LUXEMBOURG – 25 September, 2020 – Inceptua Group – pharmaceutical company and service partner announces that the European Commission (EC) has approved the transfer of the marketing authorisation for Jetrea®…

Inceptua GroupSeptember 25, 2020

Featured Press release

Inceptua Group Announces Partnership with BioCryst on Expanded Access Program for Patients with Hereditary Angioedema

LUXEMBOURG – June 26, 2020 –Inceptua Group – pharmaceutical company and service partner spanning throughout the product lifecycle – from clinical trial comparator sourcing, packaging, labelling, and distribution solutions, through…

Inceptua GroupJune 26, 2020

Featured Press release

Global License Agreement a Building Block in Strategic Growth Plans

LUXEMBOURG – 23 March, 2020 – Inceptua – pharmaceutical company and service partner - and biopharmaceutical company Oxurion have announced a global license agreement for the commercialization of JETREA®, a…

Inceptua GroupMarch 23, 2020

Clinical Trial Services Featured

How we are supporting with uninterrupted supply of medicines for clinical trials

In clinical trials, a Comparator drug, either an investigational or marketed product, is often required to determine the efficacy relative to a drug that is already on the market. Safe,…

Inceptua GroupMarch 22, 2020

Featured Press release

Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®

Press release: Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA® Oxurion announces the signing of a JETREA® global license agreement with Inceptua Group. JETREA® is…

Inceptua GroupMarch 13, 2020

Featured Medicines Access

Industry Trends in Pre-approval Access to Medicines

Expanded Access as a Key Component in the Development and Launch Process On February 20, 2020, Inceptua hosted a webinar on industry trends in pre-approval access to medicines. You…

Stuart BellMarch 3, 2020

Featured Press release

Inceptua and Portola enter exclusive distribution agreement for Ondexxya®

LUXEMBOURG / SAN FRANCISCO – 7th February 2020 – Inceptua, a global pharmaceutical company and service partner and Portola - US developer and manufacturer of therapeutic agents focusing on thrombosis…

Inceptua GroupFebruary 7, 2020

Featured Press release

Inceptua appoints new Head of Asia-Pacific, Clinical Trial Services

Inceptua has offices in both Japan and China where the regional Clinical Trial Services Team provides strategic sourcing and supply of clinical trial materials with associated clinical packaging and labelling…

Inceptua GroupFebruary 5, 2020

1 2 Next